Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts
- PMID: 32640124
- DOI: 10.1056/NEJMoa1915341
Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts
Abstract
Background: Baloxavir marboxil (baloxavir) is a polymerase acidic protein (PA) endonuclease inhibitor with clinical efficacy in the treatment of uncomplicated influenza, including in outpatients at increased risk for complications. The postexposure prophylactic efficacy of baloxavir in the household setting is unclear.
Methods: We conducted a multicenter, double-blind, randomized, placebo-controlled trial to evaluate the postexposure prophylactic efficacy of baloxavir in household contacts of index patients with confirmed influenza during the 2018-2019 season in Japan. The participants were assigned in a 1:1 ratio to receive either a single dose of baloxavir or placebo. The primary end point was clinical influenza, as confirmed by reverse-transcriptase-polymerase-chain-reaction testing, over a period of 10 days. The occurrence of baloxavir-selected PA substitutions associated with reduced susceptibility was assessed.
Results: A total of 752 household contacts of 545 index patients were randomly assigned to receive baloxavir or placebo. Among the index patients, 95.6% had influenza A virus infection, 73.6% were younger than 12 years of age, and 52.7% received baloxavir. Among the participants who could be evaluated (374 in the baloxavir group and 375 in the placebo group), the percentage in whom clinical influenza developed was significantly lower in the baloxavir group than in the placebo group (1.9% vs. 13.6%) (adjusted risk ratio, 0.14; 95% confidence interval [CI], 0.06 to 0.30; P<0.001). Baloxavir was effective in high-risk, pediatric, and unvaccinated subgroups of participants. The risk of influenza infection, regardless of symptoms, was lower with baloxavir than with placebo (adjusted risk ratio, 0.43; 95% CI, 0.32 to 0.58). The incidence of adverse events was similar in the two groups (22.2% in the baloxavir group and 20.5% in the placebo group). In the baloxavir group, the viral PA substitutions I38T/M or E23K were detected in 10 (2.7%) and 5 (1.3%) participants, respectively. No transmission of these variants from baloxavir-treated index patients to participants in the placebo group was detected; however, several instances of transmission to participants in the baloxavir group could not be ruled out.
Conclusions: Single-dose baloxavir showed significant postexposure prophylactic efficacy in preventing influenza in household contacts of patients with influenza. (Funded by Shionogi; Japan Primary Registries Network number, JapicCTI-184180.).
Copyright © 2020 Massachusetts Medical Society.
Comment in
-
Baloxavir for Postexposure Prophylaxis against Influenza in Households.N Engl J Med. 2020 Jul 23;383(4):389-390. doi: 10.1056/NEJMe2022702. Epub 2020 Jul 8. N Engl J Med. 2020. PMID: 32640147 No abstract available.
-
Neue Tablette zur Einmalgabe verhindert Influenza-Infektion.MMW Fortschr Med. 2020 Nov;162(19):26-28. doi: 10.1007/s15006-020-4497-2. MMW Fortschr Med. 2020. PMID: 33140344 Free PMC article. Review. German. No abstract available.
Similar articles
-
Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents.N Engl J Med. 2018 Sep 6;379(10):913-923. doi: 10.1056/NEJMoa1716197. N Engl J Med. 2018. PMID: 30184455 Clinical Trial.
-
Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial.Lancet Infect Dis. 2020 Oct;20(10):1204-1214. doi: 10.1016/S1473-3099(20)30004-9. Epub 2020 Jun 8. Lancet Infect Dis. 2020. PMID: 32526195 Clinical Trial.
-
Baloxavir Marboxil: The First Cap-Dependent Endonuclease Inhibitor for the Treatment of Influenza.Ann Pharmacother. 2019 Jul;53(7):754-759. doi: 10.1177/1060028019826565. Epub 2019 Jan 23. Ann Pharmacother. 2019. PMID: 30674196 Review.
-
Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018.Euro Surveill. 2019 Jan;24(3):1800698. doi: 10.2807/1560-7917.ES.2019.24.3.1800698. Euro Surveill. 2019. PMID: 30670142 Free PMC article.
-
Baloxavir: First Global Approval.Drugs. 2018 Apr;78(6):693-697. doi: 10.1007/s40265-018-0899-1. Drugs. 2018. PMID: 29623652 Review.
Cited by
-
Comparative Effectiveness of Baloxavir Marboxil and Oseltamivir Treatment in Reducing Household Transmission of Influenza: A Post Hoc Analysis of the BLOCKSTONE Trial.Influenza Other Respir Viruses. 2024 May;18(5):e13302. doi: 10.1111/irv.13302. Influenza Other Respir Viruses. 2024. PMID: 38706384 Free PMC article. Clinical Trial.
-
Study on the clinical efficacy and safety of baloxavir marboxil tablets in the treatment of influenza A.Front Med (Lausanne). 2024 Apr 5;11:1339368. doi: 10.3389/fmed.2024.1339368. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38646560 Free PMC article.
-
Household Influenza Transmission and Healthcare Resource Utilization Among Patients Treated with Baloxavir vs Oseltamivir: A United States Outpatient Prospective Survey.Infect Dis Ther. 2024 Apr;13(4):685-697. doi: 10.1007/s40121-024-00937-y. Epub 2024 Mar 14. Infect Dis Ther. 2024. PMID: 38483775 Free PMC article.
-
Prospective observational study of baloxavir marboxil in adults and adolescents with uncomplicated influenza from China.Front Microbiol. 2023 Nov 27;14:1292735. doi: 10.3389/fmicb.2023.1292735. eCollection 2023. Front Microbiol. 2023. PMID: 38088961 Free PMC article.
-
Prophylactic Treatment with Baloxavir Protects Mice from Lethal Infection with Influenza A and B Viruses.Viruses. 2023 Nov 16;15(11):2264. doi: 10.3390/v15112264. Viruses. 2023. PMID: 38005940 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical